<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        283-212-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MONTEL 4MG CHEWABLE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        88.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Organon Pharma (UK) Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Organon Pharma (UK) Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MONTEL is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, MONTEL improves asthma symptoms and helps control asthma.</p><p>&nbsp;</p><p>Your doctor has prescribed MONTEL to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MONTEL is used for the treatment of 2 to 5 year old patients who are not adequately controlled on their medication and need additional therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MONTEL may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MONTEL also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Montelukast Paediatric is used to treat outdoor allergies that happen part of the year (seasonal allergic rhinitis) in children 2 to 5 years of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Montelukast Paediatric is used to treat indoor allergies that happen all year (perennial allergic rhinitis) in children 2 to 5 years of age.</p><p>Your doctor will determine how MONTEL should be used depending on the symptoms and severity of your child&#39;s asthma.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>What is asthma?</strong></p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling (inflammation) in the lining of the airways.</p><p>Symptoms of asthma include:<strong> </strong>Coughing, wheezing, and chest tightness.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or has had.</p><p>&nbsp;</p><p><strong>Do not give MONTEL to your child if he/she</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is allergic (hypersensitive) to montelukast or any of the other ingredients of MONTEL (see&nbsp;6. FURTHER INFORMATION).</p><p>&nbsp;</p><p><strong>Take special care with MONTEL</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral MONTEL is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that your child take all asthma medications prescribed by your doctor. MONTEL should not be used instead of other asthma medications your doctor has prescribed for your child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</p><p>&nbsp;</p><p>Patients should be aware that various neuropsychiatric events (for example behaviour and mood<strong>-</strong>related changes) have been reported in adults, adolescents and children with Montel (see section 4).</p><p>If your child develops such symptoms while taking Montel, you should consult your child&rsquo;s doctor.</p><p><strong>Children and adolescents </strong></p><p>Do not give this medicine to children less than 2 years of age.</p><p>There are different form(s) of this medicine available for paediatric patients under 18 years of age</p><p>based on age range.</p><p><strong>Taking other medicines</strong></p><p>Some medicines may affect how MONTEL works, or MONTEL may affect how your child&rsquo;s other medicines work.</p><p>&nbsp;</p><p>Please tell your doctor or pharmacist if your child is taking or has recently taken other medicines, including those obtained without a prescription.</p><p>&nbsp;</p><p>Tell your doctor if your child is taking the following medicines before starting MONTEL:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenobarbital (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (used for treatment of epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat tuberculosis and some other infections)</p><p>&nbsp;</p><p><strong>Taking MONTEL with food and drink</strong></p><p>MONTEL4&nbsp;mg chewable tablets should not be taken immediately with food; they should be taken at least 1 hour before or 2&nbsp;hours after food.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>This subsection is not applicable for the MONTEL4&nbsp;mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p>&nbsp;</p><p><em>Use in pregnancy</em></p><p>Women who are pregnant or intend to become pregnant should consult their doctor before taking MONTEL. Your doctor will assess whether you can take MONTEL during this time.</p><p>&nbsp;</p><p><em>Use in breast-feeding</em></p><p>It is not known if MONTEL appears in breast milk. You should consult your doctor before taking MONTEL if you are breast-feeding or intend to breast-feed.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This subsection is not applicable for the MONTEL4&nbsp;mg chewable tablets since they are intended for use in children 2 to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p>MONTEL is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported very rarely with MONTEL may affect some patients&rsquo; ability to drive or operate machinery.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong>Important information about some of the ingredients of MONTEL</strong></p><p>MONTEL chewable tablets contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare, hereditary disorder of the metabolism) you should take into account that each 4-mg chewable tablet contains phenylalanine (equivalent to 0.674&nbsp;mg phenylalanine per 4&nbsp;mg chewable tablet).</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><u>&nbsp;</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, an oral granule formulation is available.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your child should take only one tablet of MONTEL once a day as prescribed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always have your child take MONTEL as your doctor has told you. You should check with your child&rsquo;s doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To be taken by mouth</p><p><strong><u>&nbsp;</u></strong></p><p><strong>For children 2 to 5 years of age:</strong></p><p>One 4&nbsp;mg chewable tablet daily to be taken in the evening. MONTEL 4&nbsp;mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2 hours after food.</p><p>If your child is taking MONTEL, be sure that he/she does not take any other medicines that contain the same active ingredient, montelukast.</p><p>The tablets are to be chewed before swallowing.</p><p>The MONTEL 4&nbsp;mg chewable tablet is not recommended below 2 years of age.</p><p>&nbsp;</p><p><strong>If your child takes more MONTEL than he/she should</strong></p><p>Contact your child&rsquo;s doctor immediately for advice.</p><p>There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.</p><p>&nbsp;</p><p><strong>If you forget to give MONTEL to your child</strong></p><p>Try to give MONTEL as prescribed. However, if your child misses a dose, just resume the usual schedule of one tablet once daily.</p><p>Do not give a double dose to make up for a forgotten dose.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>If your child stops taking MONTEL</strong></p><p>MONTEL can treat your child&rsquo;s asthma only if he/she continues taking it.</p><p>It is important for your child to continue taking MONTEL for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this product, ask your child&rsquo;s doctor or pharmacist.</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, MONTEL can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>In clinical studies with MONTEL4&nbsp;mg chewable tablets, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to MONTEL were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p>Additionally, the following side effect was reported in clinical studies with MONTEL 10&nbsp;mg film-coated tablets and 5&nbsp;mg chewable tablets:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>These were usually mild and occurred at a greater frequency in patients treated with MONTEL than placebo (a pill containing no medication).</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Talk with your doctor immediately </strong>if you notice any of the following side effects with your</p><p>child, which may be serious, and for which your child may need urgent medical treatment.</p><p>&nbsp;</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause</p><p>difficulty in breathing or swallowing</p><p>&bull; behaviour and mood related changes: agitation including aggressive behaviour or hostility,</p><p>depression</p><p>&bull; seizure</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; increased bleeding tendency</p><p>&bull; tremor</p><p>&bull; palpitations</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; combination of symptoms such as flu-like illness, pins and needles or numbness of arms and</p><p>legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) (see section 2)</p><p>&bull; low blood platelet count</p><p>&bull; behaviour and mood related changes: hallucinations, disorientation, suicidal thoughts and</p><p>actions</p><p>&bull; swelling (inflammation) of the lungs</p><p>&bull; severe skin reactions (erythema multiforme) that may occur without warning</p><p>&bull; inflammation of the liver (hepatitis)</p><p>&nbsp;</p><p><strong>Other side effects while the medicine has been on the market</strong></p><p>Very common: the following may affect more than 1 in 10 people</p><p>&bull; upper respiratory infection</p><p>Common: the following may affect up to 1 in 10 people</p><p>&bull; diarrhoea, nausea, vomiting</p><p>&bull; rash</p><p>&bull; fever</p><p>&bull; elevated liver enzymes</p><p>Uncommon: the following may affect up to 1 in 100 people</p><p>&bull; behaviour and mood related changes: dream abnormalities, including nightmares, trouble</p><p>sleeping, sleepwalking, irritability, feeling anxious, restlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, drowsiness, pins and needles/numbness</p><p>&bull; nosebleed</p><p>&bull; dry mouth, indigestion</p><p>&bull; bruising, itching, hives</p><p>&bull; joint or muscle pain, muscle cramps</p><p>&bull; bedwetting in children</p><p>&bull; weakness/tiredness, feeling unwell, swelling</p><p>Rare: the following may affect up to 1 in 1,000 people</p><p>&bull; behaviour and mood related changes: disturbance in attention, memory</p><p>impairment, uncontrolled muscle movements</p><p>Very rare: the following may affect up to 1 in 10,000 people</p><p>&bull; tender red lumps under the skin, most commonly on your shins (erythema nodosum)</p><p>&bull; behaviour and mood related changes: obsessive-compulsive symptoms, stuttering.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for more information about side effects. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your child&rsquo;s doctor or pharmacist.</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the 4-mg chewable tablets at room temperature 15-30&deg;C (59-86&deg;F). &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the date shown by the six numbers following EXP on the blister. The first two numbers indicate the month; the last four numbers indicate the year. This medicine expires at the end of the month shown.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light and moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is montelukast. Each tablet contains montelukast sodium which corresponds to 4&nbsp;mg of montelukast.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Mannitol, microcrystalline cellulose, hyprolose (E 463), red ferric oxide (E 172), croscarmellose sodium, cherry flavour, aspartame (E951), and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                4 mg MONTEL Chewable tablet , pink, oval, bi-convex-shaped, 711 engraved on one side.

Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 140 and 200 tablets.
Blisters (unit doses), in packages of: 49, 50 and 56 tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p>Organon Pharma (UK) Limited, Shotton Lane,</p><p>Cramlington, Northumberland, NE23 3JU,</p><p>UK.</p><p><strong>Marketing Authorization Holder</strong></p><p><strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">مونتيل عبارة عن مضاد لمستقبلات الليوكوترايين والتي تمنع مواد تدعى الليوكوترايين. الليوكوترايينات تسبب ضيق وتورم مجرى التنفس في الرئتين وتسبب أيضاً أعراض الحساسية. وبمنع الليوكوترايين، فإن مونتيل يحسن أعراض الربو، ويساعد على السيطرة على الربو ويحسن أعراض الحساسية الموسمية (والتي تعرف بحمى القش أو سيلان الأنف التحسسي الموسمي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وصف لك الطبيب مونتيل لعلاج الربو، ولمنع ظهور أعراض الربو أثناء النهار والليل.</p><ul><li dir="RTL">يستخدم مونتيل لعلاج المرضى الذين تتراوح أعمارهم من 2 إلى 5 سنوات والذين لا يستجيبون بصورة كافية لأدوية الربو التي يستخدمونها و بالتالي فهم بحاجة لعلاج إضافي.</li><li dir="RTL">قد يستخدم مونتيل كعلاج بديل للستيرويد المستنشق للأطفال الذين هم بين سنتين و خمسة سنوات والذين لم يتناولوا حديثاً كورتيكوستيرويد بالفم لعلاج الربو واتضح أنهم غير قادرين على استخدام الكورتيكوستيرويد المستنشق.</li><li dir="RTL">يساعد مونتيل أيضاً على منع تضيق مجاري التنفس التي تتهيج بأداء التمارين الرياضية لدى المرضى الذين تبلغ أعمارهم سنتين فأكثر.</li><li dir="RTL">يستخدم مونتيلوكاست للأطفال في علاج الحساسية الخارجية التي تحدث في فترة من السنة (حساسية الأنف الموسمية) في الأطفال من سن سنتين إلى خمس سنوات من العمر.</li><li dir="RTL">يستخدم مونتيلوكاست للأطفال في علاج الحساسية الداخلية التي تحدث طوال السنة (حساسية الأنف الدائمة) في الأطفال من سن سنتين إلى خمس سنوات من العمر.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد لك الطبيب كيف تستخدم مونتيل إعتماداً على الأعراض وعلى شدة مرض الربو لدى طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهو الربو؟</strong></p><p dir="RTL">الربو هو مرض رئوي مزمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويشمل مرض الربو ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس بسبب ضيق في مجاري التنفس. ويزداد هذا الضيق سوءاً أو يتحسن نتيجة لحالات مختلفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجري التنفس الحساس يتأثر بالعديد من المؤثرات، مثل دخان السجائر، حبوب اللقاح، برودة الجو، أو التمارين الرياضية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) بطانة مجرى التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتشمل أعراض الربو ما يلي: السعال، أزيز وضيق في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية إبنك مصاب بها الآن أو أصيب بها مسبقاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تعطي مونتيل لطفلك إذا كان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساساً (زيادة الحساسية) لمونتيلوكاست أو أي من المواد الموجودة في مونتيل (أنظر فقرة 6. معلومات إضافية)</p><p dir="RTL">&nbsp;</p><p>اتبع عناية خاصة مع مونتيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تدهورت حالة الربو أو التنفس لدى طفلك فأخبر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يقصد بمونتيل كعلاج لنوبات الربو المفاجئة. إذا حدثت النوبة، اتبع تعليمات الطبيب التي ذكرها لك بخصوص طفلك. ومن المهم أن يكون دواء الإنقاذ السريع المستنشق للربو جاهزاً معك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن يتناول إبنك جميع أدوية الربو التي وصفها الطبيب حسب حاجتها، ولا يجب الإستعاضة بمونتيل عن أدوية الربو الأخرى التي وصفها لك الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان ابنك يتناول أدوية الربو يجب أن تتنبه وتخبر طبيبك عند حدوث مجموعة من الأعراض مثل مرض يشبه مرض الإنفلونزا، الشعور بوخز أو خدر في الذراعين أوالساقين، تدهور الأعراض الصدرية، و/أو طفح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب أن يتناول ابنك الأسبرين (حمض الأسيتايل ساليسيليك) أو الأدوية الأخرى الغير ستيرويدية إذا أدت إلى تدهور حالة الربو لديه أو لديها.</p><p dir="RTL">ينبغي أن يدرك المرضى ﺑﺄنه تم الإبلاغ عن الأحداث العصبية النفسية المختلفة (علي سبيل المثال, السلوك و التغيرات المتعلقة ﺑﺎلمزاج) لدى البالغين والمراهقين والأطفال مع مونتيل (انظر القسم 4). إذا كنت تواجه مثل هذه الأعراض أثناء تناول مونتيل، يجب استشارة الطبيب.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا تعطِ الدواء للأطفال أقل من عمر عامين.</p><p dir="RTL">هناك أشكال صيدلانية مختلفة لهذا الدواء للمرضى الأطفال تحت عمر 18 سنة على أساس الفئة العمرية<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">قد تؤثر بعض الأدوية على طريقة عمل مونتيل، أو قد يؤثر مونتيل على طريقة عمل الأدوية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تخبر طبيبك أو الصيدلي عن جميع الأدوية التي يتناولها طفلك أو تناولها حديثاً، بما في ذلك الأدوية التي تحصل عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كان طفلك يتناول الأدوية التالية قبل البدء بتناول مونتيل:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (يستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينايتوين (يستخدم لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل وبعض العدوى)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول مونتيل مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم تناول أقراص مونتيل للمضغ 4 ملجم مع الطعام في الحال، يجب أن يتم تناوله إما ساعة قبل الأكل أو ساعتين بعده.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الفقرة لا تنطبق على مونتيل أقراص للمضغ تركيز 4 ملجم لأنها مصنعة للإستخدام من قبل الأطفال الذين تبلغ أعمارهم من 2 إلى 5 سنوات، ومع ذلك، فالمعلومات التالية تتعلق بالمادة الفعالة مونتيلوكاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدامه في الحمل</p><p dir="RTL">على النساء الحوامل أو اللواتي يرغبن بالحمل استشارة الطبيب قبل تناول مونتيل.</p><p dir="RTL">فطبيبك سيحدد ما إذا كان بالإمكان تناول مونتيل في ذلك الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدامه أثناء الرضاعة</p><p dir="RTL">لا يعرف ما إذا كان مونتيل يفرز في حليب المرضعات أم لا. ويجب استشارة الطبيب قبل تناول &quot; مونتيل&quot;، وذلك إذا كنت مرضعة أو تنوين إرضاع طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات وتشغيل الآلات</strong></p><p dir="RTL">هذه الفقرة لا تنطبق على مونتيل أقراص للمضغ 4 ملجم لأنها مصنعة للإستخدام من قبل الأطفال الذين تبلغ أعمارهم من 2 إلى 5 سنوات، ومع ذلك، فالمعلومات التالية تتعلق بالمادة الفعالة مونتيلوكاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتوقع أن يؤثر مونتيل في قدرتك على قيادة السيارات وتشغيل الآلات. وعلى كل حال، فقد تختلف الإستجابة للدواء من شخص لآخر. وبعض الآثار الجانبية (مثل الدوار والدوخة) سجلت بصورة نادرة جدامع مونتيل قد تؤثر على قدرة المريض على قيادة السيارات أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات مونتيل</strong></p><p dir="RTL">أقراص مونتيل المضغ للأطفال تحتوي على أسبارتام، وهو مصدر للفينايل آلانين.</p><p dir="RTL">إذا كان طفلك مصاباً بالفينايل كيتون يوريا (وهو مرض وراثى نادر فى عملية الأيض) فيجب الأخذ بالحسبان أن كل قرص مضغ من مونتيل 4 ملجم يحتوي على فينايل آلانين (يكافئ 0.674 ملجم فينايل آلانين لكل قرص مضغ 4 ملجم).</p><p dir="RTL">هذا الدواء يحتوي علي أقل من 1 ملليمول صوديوم (23 ملجم) للقرص الواحد، وهذا يعني ﺑﺄنه أساسا &quot; خالٍ من الصوديوم &quot;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يتم إعطاء هذا الدواء تحت الإشراف الطبي، بالنسبة للأطفال الذين يواجهون مشكلة في تناول أقراص المضغ، فهناك حبيبات بالفم متوفرة كبديل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يتناول طفلك مونتيل مرة يومياً حسب تعليمات الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يتناوله طفلك أيضاً في حالة إختفاء الأعراض أو في نوبات الربو المفاجئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اجعل طفلك دوماً يتناول مونتيل كما وصف لك الطبيب. وعليك التوثق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناوله بالفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بالنسبة للأطفال الذين تتراوح أعمارهم من 2 إلى 5 سنوات</strong></p><p dir="RTL">يجب تناول قرص واحد للمضغ من مونتيل بالفم تركيز 4 ملجم يومياً في المساء، يجب عدم تناول مونتيل 4 ملجم أقراص للمضغ حالاً مع الطعام. يجب تناولها إما قبل الطعام بساعة أو بعده بساعتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان طفلك يتناول مونتيل، توثق من أن طفلك لا يتناول منتج آخر يحتوي على نفس المادة الفعالة، مونتيلوكاست.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب مضغ الأقراص قبل بلعها.</p><p dir="RTL">لا يوصى باستخدام أقراص مونتيل للمضغ تركيز 4 ملجم للأطفال دون سن سنتين.</p><p dir="RTL">&nbsp;</p><p>إذا تناول طفلك الكثير من مونتيل عن طريق الخطأ</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك فوراً طلبا للمساعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تسجل أي أثار عكسية مع معظم تقارير الجرعة الزائدة. وأكثر الآثار الجانبية التي تم تسجيل وقوعها مع الجرعة الزائدة في الكبار والأطفال شملت ألم البطن، نعاس، عطش، صداع، تقيؤ، وفرط النشاط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تعطي طفلك مونتيل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">حاول أن تعطي مونتيل كما هو موصوف لك. وعلى العموم، إذا نسي الطفل تناول الجرعة، تابع الجدول المعتاد للجرعة وهو قرص واحد مرة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تعطي جرعة إضافية لتعوض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقف طفلك عن تناول مونتيل</strong></p><p dir="RTL">يمكن أن يعالج مونتيل مرض الربو لدى طفلك فقط إذا داوم على تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم لطفلك أن يستمر بتناول مونتيل طوال الفترة التي وصفها الطبيب لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يساعد في السيطرة على مرض الربو لدى طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة إضافية حول استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، فإن مونتيل قد يسبب آثاراً جانبية، والتي قد لا تحدث مع جميع المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وفي الدراسات الإكلينيكية المتعلقة بأقراص مونتيل 4 ملجم للمضغ، وجد أن غالبية الآثار الجانبية شيوعاً المسجلة (تحدث في أكثر من 1 في كل 100، و أقل من 1 لكل 10 مرضى) والتي تتعلق بالعلاج بمونتيل هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش</p><p dir="RTL">&nbsp;</p><p dir="RTL">إضافة لذلك، تم تقرير الآثار الجانبية التالية في الدراسات الإكلينيكية التي اجريت على مونتيل 10 ملجم أقراص مغلفة بغشاء رقيق، مونتيل 5 ملجم أقراص للمضغ:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه كانت بسيطة وحدثت بغالبية أكبر في المرضى الذين أعطوا مونتيل مقارنة بالعلاج الوهمي (القرص الذي لا يحتوي على دواء).</p><p dir="RTL"><strong>الأعراض الجانبيّة الخطيرة</strong></p><p dir="RTL">تحدث مع طبيبك على الفور إذا لاحظت أي من الآﺛﺎر الجانبية التالية مع طفلك، والتي قد تكون خطيرة، والتي قد يحتاج طفلك إلى علاج طبي عاجل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (تؤثّر على واحد من أصل 100 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية بما في ذلك تورم في الوجه, الشفتين, اللسان, و/أو الحلق الذي قد يسبب صعوبة في التنفس أو البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في السلوك والمزاج ذات الصلة: الانفعالات بما في ذلك السلوك العدواني أو العداء، والاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (تؤثّر على واحد من أصل 1000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة احتمالية النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة جداً (تؤثر على واحد من أصل 10000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزيج من الأعراض مثل المرض المشابه للإنفلونزا، والوخز أو خدر الذراعين والساقين, وتفاقم الأعراض الرئوية و/أو الطفح الجلدي (متلازمة شيرغ ستراوس) (انظر الفقرة 2)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في السلوك والمزاج ذات الصلة: الهلوسة, الارتباك, الأفكار الانتحارية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (التهاب) الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل الجلدية الشديدة (حمامى متعددة الأشكال) التي قد تحدث دون سابق إنذار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الوبائي</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالإضافة إلى ذلك، تمّ الابلاغ عن الأعراض الجانبيّة التالية بينما كان الدواء مطروحًا في السوق:</p><p dir="RTL">شائعة جدًا (تؤثّر على أكثر من واحد من أصل 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (تؤثّر على واحد من أصل 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال والغثيان والقيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع إنزيمات الكبد</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير شائعة (تؤثّر على واحد من أصل 100 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في السلوك والمزاج ذات الصلة: اضطراﺑﺎت في الأحلام، بما في ذلك الكوابيس، وصعوبة في النوم، المشي خلال النوم، والتهيج، والشعور ﺑﺎلقلق، والأرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة والنعاس و الوخز/خدر ورعاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات, حكه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الام المفاصل أو العضلات، تشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبول لاإرادي في الأطفال, الضعف /التعب، والشعور بتوعك، وتورم</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرة (تؤثّر على واحد من أصل 1000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في السلوك والمزاج ذات الصلة: اضطراب في الاهتمام, ضعف الذاكرة, حركات العضلات غير المنضبط</p><p dir="RTL">نادرة جدًّا (تؤثّر على واحد من أصل 10000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود كتل حمراء طرية تحت الجلد، والأكثر شيوعا (حمامى عقدة) على السيقان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في السلوك والمزاج ذات الصلة: اعراض الوسواس القهري، التاﺗﺎه</p><p dir="RTL">&nbsp;</p><p dir="RTL">اطلب من طبيبك أو الصيدلي معلومات إضافية حول الآثار الجانبية. إذا أصبحت أي من الآثار الجانبية أكثر سوءاً، أو إذا عانيت من أي أعراض غير مذكورة في النشرة، فأبلغ طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;يتم تخزين أقراص المضغ تركيز 4 ملجم، عند درجة حرارة 15 &ndash; 30 درجة مئوية (59 &ndash; 86 ف).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم حفظها بعيداً عن أيدي ونظرالأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول الأقراص بعد تاريخ الانتهاء الموضح بستة أرقام بعد كلمة EXP على الشريط. أول عددين تمثل الشهر، وآخر 4 أعداد تمثل السنة. وبذلك تنتهي صلاحية الدواء بنهاية الشهر المدون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظه في العبوة الأصلية لتحميه من الضوء والرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد بحاجتها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعّالة: مونتيلوكاست. كل قرص يحتوي على مونتيلوكاست الصوديوم والذي يعادل 4 ملجم من مونتيلوكاست.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكونات أخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مانيتول، سيليلوز دقيق البلورات، هيبرولوز (E463)، أكسيد الحديد الأحمر (E172)، كروس ماللوز الصوديوم، نكهة الكرز، أسبارتام (E951)، &nbsp;وستياريت المغنيسيوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص مونتيل 4 ملجم للمضغ وردية، بيضاوي محدبة الوجهين، محفور على وجه واحد 711.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأشرطة بعبوات تحتوي على 7، 10، 14 20، 28 و 30 ، 50، 56، 98، 100، 140، و200 قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أشرطة (الجرعة الواحدة)، في عبوات: 49، 50 و 56 قرص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">أورجانون فارما (المملكة المتحدة) ليميتد، شوتون لين،</p><p dir="RTL">كراملينجتون، نورثمبرلاند، إن إي ٣٣٢ جي يو،</p><p dir="RTL">المملكة المتحد ة<strong> </strong></p><p dir="RTL"><strong>مالك الحقوق التسويقية</strong><strong>:</strong><strong> </strong></p><p dir="RTL"><strong>الدوائية </strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2022 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MONTEL 4 mg chewable tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One chewable tablet contains montelukast sodium, which is equivalent to 4 mg montelukast.
Excipient: Aspartame (E 951) 1.2 mg per tablet.

This medicine contains less than 1mmol sodium (23 mg) per tablet, that is to say
essentially ‘sodium-free’.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Chewable tablet 

Pink, oval, bi-convex-shaped, 711 engraved on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>MONTEL is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting b‑agonists provide inadequate clinical control of asthma.</p><p>&nbsp;</p><p>MONTEL may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5&nbsp;year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section&nbsp;4.2).</p><p>&nbsp;</p><p>MONTEL is also indicated in the prophylaxis of asthma from 2&nbsp;years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p><p>&nbsp;</p><p>MONTEL 4&nbsp;mg chewable tablets is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 to 5 years of age and perennial allergic rhinitis in patients 2 to 5 years of</p><p>age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, a granule formulation is available (see MONTEL4&nbsp;mg granule SPC). The dosage for paediatric patients 2-5&nbsp;years of age is one 4&nbsp;mg chewable tablet daily to be taken in the evening. If taken in connection with food, MONTEL should be taken 1&nbsp;hour before or 2 hours after food. No dosage adjustment within this age group is necessary. MONTEL 4&nbsp;mg chewable tablet formulation is not recommended below 2 years of age.</p><p><em>&nbsp;</em></p><p><em>General recommendations. </em></p><p>The therapeutic effect of MONTEL on parameters of asthma control occurs within one day. Patients should be advised to continue taking MONTEL even if their asthma is under control, as well as during periods of worsening asthma.</p><p>&nbsp;</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p>&nbsp;</p><p><em>MONTEL as an alternative treatment option to low-dose inhaled corticosteroids for mild, persistent </em><em>asthma</em>:</p><p>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section&nbsp;4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less that once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><em>&nbsp;</em></p><p><em>MONTEL as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant component is exercise-induced bronchoconstriction:</em></p><p>In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p>&nbsp;</p><p><em>Therapy with MONTEL in relation to other treatments for asthma.</em></p><p>When treatment with MONTEL is used as add-on therapy to inhaled corticosteroids, MONTEL should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p>&nbsp;</p><p>10&nbsp;mg film-coated tablets are available for adults 15&nbsp;years of age and older.</p><p>5&nbsp;mg chewable tablets are available for paediatric patients 6 to 14&nbsp;years of age.</p><p>4&nbsp;mg granules are available for paediatric patients 6 months to 5&nbsp;years of age.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Do not give MONTEL 4 mg chewable tablets to children less than 2 years of age. The</p><p>safety and efficacy of MONTEL 4 mg chewable tablets in children less than 2 years of</p><p>age has not been established.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>The tablets are to be chewed before swallowing.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled b‑agonist should be used. Patients should seek their doctors&rsquo; advice as soon as possible if they need more inhalations of short-acting b-agonists than usual.</p><p>&nbsp;</p><p>Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p>&nbsp;</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>&nbsp;</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases usually, but not always, have been associated with the reduction or withdrawal of oral corticosteroid therapy. The possibility that leukotriene receptor antagonists may be associated with emergence of Churg-Strauss syndrome can neither be excluded nor established. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>&nbsp;</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive</p><p>asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p>&nbsp;</p><p>MONTEL contains aspartame, a source of phenylalanine. Patients with phenylketonuria should take into account that each 4&nbsp;mg chewable tablet contains phenylalanine in an amount equivalent to 0.674&nbsp;mg phenylalanine per dose.</p><p>&nbsp;</p><p>Neuropsychiatric events have been reported in adults, adolescents, and children taking</p><p>MONTEL (see section 4.8). Patients and physicians should be alert for neuropsychiatric</p><p>events. Patients and/or caregivers should be instructed to notify their physician if these</p><p>changes occur. Prescribers should carefully evaluate the risks and benefits of continuing</p><p>treatment with MONTEL if such events occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone&nbsp;35/1), terfenadine, digoxin and warfarin.</p><p>&nbsp;</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co‑administration of phenobarbital. Since montelukast is metabolised by CYP&nbsp;3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is coadministered with inducers of CYP&nbsp;3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p>&nbsp;</p><p>In vitro studies have shown that montelukast is a potent inhibitor of CYP&nbsp;2C8. However, data from a clinical drug‑drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolized by CYP&nbsp;2C8) demonstrated that montelukast does not inhibit CYP&nbsp;2C8 in vivo. Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolized by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide.)</p><p>&nbsp;</p><p>In&nbsp;vitro studies have shown that montelukast is a substrate of CYP&nbsp;2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug‑drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP&nbsp;2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co-administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>&nbsp;</p><p>Based on in&nbsp;vitro data, clinically important drug interactions with less potent inhibitors of CYP&nbsp;2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Use during pregnancy</em></p><p>&nbsp;</p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.&nbsp;</p><p>&nbsp;</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between MONTEL and malformations (i.e. limb defects) that have been rarely reported in worldwide post marketing experience.&nbsp;</p><p>&nbsp;</p><p>MONTEL may be used during pregnancy only if it is considered to be clearly essential.</p><p>&nbsp;</p><p><em>&nbsp;Use during lactation</em></p><p>&nbsp;</p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is not known if montelukast is excreted in human milk.</p><p>&nbsp;</p><p>MONTEL may be used in breast-feeding mothers only if it is considered to be clearly essential.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast is not expected to affect a patient&rsquo;s ability to drive a car or operate machinery. However, in very rare cases, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><p>&sect;&nbsp; 10&nbsp;mg film-coated tablets in approximately 4000&nbsp;adult patients 15&nbsp;years of age and older</p><p>&sect;&nbsp; 5&nbsp;mg chewable tablets in approximately 1750&nbsp;paediatric patients 6 to 14&nbsp;years of age, and</p><p>&sect;&nbsp; 4&nbsp;mg chewable tablets in 851&nbsp;paediatric patients 2 to 5&nbsp;years of age.</p><p>Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><p>&sect;&nbsp; 4&nbsp;mg granules and chewable tablets in 1038&nbsp;paediatric patients 6 months to 5&nbsp;years of age</p><p>&nbsp;</p><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:636px"><thead><tr><td><p><strong>Body System Class</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Adult Patients</strong></p><p><strong>15 years and older</strong></p><p><strong>(two 12-week studies;</strong></p><p><strong>n=795)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Paediatric Patients</strong></p><p><strong>6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56 week studies; n=615)</strong></p></td><td><p><strong>&nbsp;</strong></p><p><strong>Paediatric Patients</strong></p><p><strong>2 to 5 years old</strong></p><p><strong>(one 12-week study;</strong></p><p><strong>n=461)</strong></p><p><strong>(one 48-week study; n=278)</strong></p></td></tr></thead><tbody><tr><td><p><strong>Nervous system disorders</strong></p></td><td><p>Headache</p></td><td><p>headache</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><strong>Gastrointestinal disorders</strong></p></td><td><p>abdominal pain</p></td><td><p>&nbsp;</p></td><td><p>abdominal pain</p></td></tr><tr><td><p><strong>General disorders and administration site conditions</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>thirst</p></td></tr></tbody></table><p>&nbsp;</p><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2&nbsp;years for adults, and up to 12&nbsp;months for paediatric patients 6 to 14&nbsp;years of age, the safety profile did not change.</p><p>&nbsp;</p><p>Cumulatively, 502&nbsp;paediatric patients 2 to 5&nbsp;years of age were treated with montelukast for at least 3&nbsp;months, 338 for 6&nbsp;months or longer, and 534&nbsp;patients for 12&nbsp;months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p>&nbsp;</p><p>Post-marketing Experience</p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Experience Term, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:600px"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Adverse Experience Term</p></td><td style="vertical-align:top"><p>Frequency Category*</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection&dagger;</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorder</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism,</p><p>anxiety, agitation including aggressive behaviour or hostility, depression,</p><p>psychomotor hyperactivity (including irritability, restlessness, tremor&sect;)</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention,</p><p>memory impairment, tic</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal</p><p>thinking and behaviour (suicidality), obsessive compulsive symptoms,</p><p>dysphemia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorder</p></td><td style="vertical-align:top"><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg‑Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhoea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>enuresis in children</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema,</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).</p><p><sup>&dagger;</sup>This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p><sup>&Dagger;</sup>This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exts: 2317-2356-2340.</p><p>Hot line: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with montelukast. In chronic asthma studies, montelukast has been administered at doses up to 200&nbsp;mg/day to adult patients for 22&nbsp;weeks and in short term studies, up to 900&nbsp;mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>&nbsp;</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1000&nbsp;mg (approximately 61&nbsp;mg/kg in a 42&nbsp;month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p>&nbsp;</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety</p><p>profile of montelukast and included abdominal pain, somnolence, thirst, headache,</p><p>vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It</p><p>is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Leukotriene receptor antagonist</p><p><strong>ATC-code: </strong>R03D C03</p><p>&nbsp;</p><p>The cysteinyl leukotrienes (LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p>&nbsp;</p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT<sub>1</sub> receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD<sub>4</sub> at doses as low as 5&nbsp;mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a b‑agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late‑phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14&nbsp;years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p>&nbsp;</p><p>In studies in adults, montelukast, 10&nbsp;mg once daily, compared with placebo, demonstrated significant improvements in morning FEV<sub>1 </sub>(10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total b‑agonist use (‑26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>&nbsp;</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 5.43% vs 1.04%; b‑agonist use: ‑8.70% vs 2.64%). Compared with inhaled beclomethasone (200&nbsp;mg twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV<sub>1</sub>: 7.49% vs 13.3%; b‑agonist use: ‑28.28% vs ‑43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV<sub>1</sub> of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>&nbsp;</p><p>In a 12-week, placebo-controlled study in paediatric patients 2 to 5&nbsp;years of age, montelukast 4&nbsp;mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulized corticosteroids or inhaled/nebulized sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &quot;as-needed&quot; b-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p>&nbsp;</p><p>In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4&nbsp;mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34&nbsp;EE, respectively), [EE defined as &ge;3 consecutive days with daytime symptoms requiring b-agonist use, or corticosteroids (oral or inhaled), or hospitalization for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p>&nbsp;</p><p>In a placebo-controlled study in paediatric patients 6 months to 5&nbsp;years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12-day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p>&nbsp;</p><p>In an 8-week study in paediatric patients 6 to 14&nbsp;years of age, montelukast 5&nbsp;mg once daily, compared with placebo, significantly improved respiratory function (FEV<sub>1</sub> 8.71% vs 4.16% change from baseline; AM&nbsp;PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &quot;as-needed&quot; b‑agonist use (‑11.7% vs +8.2% change from baseline).</p><p>&nbsp;</p><p>In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14&nbsp;years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint.&nbsp; Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8&nbsp;with a 95% CI of ‑4.7, -0.9), but within the limit pre-defined to be clinically not inferior.</p><p>Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12&nbsp;month treatment period:</p><p>FEV<sub>1</sub> increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV<sub>1</sub> was -0.02&nbsp;L with a 95%&nbsp;CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV<sub>1</sub> was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV<sub>1</sub> was significant: ‑2.2% with a 95%&nbsp;CI of ‑3.6, ‑0.7.</p><p>The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with b-agonist use was significant: 2.7 with a 95% CI of 0.9,&nbsp;4.5.</p><p>The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&rsquo;s office, an emergency room visit, or hospitalization) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p>The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS&nbsp;means was significant: 7.3% with a 95%CI of 2.9; 11.7.</p><p>&nbsp;</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12-week study in adults (maximal fall in FEV<sub>1</sub> 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV<sub>1</sub> 44.22&nbsp;min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to 14&nbsp;years of age (maximal fall in FEV<sub>1</sub> 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV<sub>1</sub> 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>&nbsp;</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV<sub>1 </sub>8.55% vs -1.74% change from baseline and decrease in total b‑agonist use ‑27.78% vs 2.09% change from baseline).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption.</em><strong> </strong></p><p>Montelukast is rapidly absorbed following oral administration. For the 10&nbsp;mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved 3 hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and C<sub>max</sub> are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10&nbsp;mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>&nbsp;</p><p>For the 5&nbsp;mg chewable tablet, the C<sub>max</sub> is achieved in 2&nbsp;hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p><em>&nbsp;</em></p><p>After administration of the 4&nbsp;mg chewable tablet to paediatric patients 2 to 5&nbsp;years of age in the fasted state, C<sub>max</sub> is achieved 2&nbsp;hours after administration. The mean C<sub>max</sub> is 66% higher while mean C<sub>min</sub> is lower than in adults receiving a 10&nbsp;mg tablet.</p><p><em>&nbsp;</em></p><p><em>Distribution.</em><strong> </strong></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 liters. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24&nbsp;hours post-dose were minimal in all other tissues.</p><p><em>&nbsp;</em></p><p><em>Biotransformation. </em></p><p>Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p><em>&nbsp;</em></p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro</em> results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><em>&nbsp;</em></p><p><em>Elimination. </em></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p>&nbsp;</p><p><em>Characteristics in Patients.</em></p><p><em>&nbsp;</em>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score&nbsp;&gt;9).</p><p>&nbsp;</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10&nbsp;mg once daily.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150&nbsp;mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200&nbsp;mg/kg/day (&gt;69‑fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>&nbsp;</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000&nbsp;mg/kg in mice and rats (15,000&nbsp;mg/m<sup>2</sup> and 30,000&nbsp;mg/m<sup>2</sup> in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000&nbsp;times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>&nbsp;</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500&nbsp;mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p><strong>&nbsp;</strong></p><p>Montelukast was neither mutagenic in <em>in vitro</em> and <em>in vivo </em>tests nor tumorigenic in rodent species.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Microcrystalline cellulose</p><p>Hyprolose&nbsp;(E 463)</p><p>Red ferric oxide&nbsp;(E 172)</p><p>Croscarmellose sodium</p><p>Cherry flavour</p><p>Aspartame&nbsp;(E 951)</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store the 4-mg chewable tablets at room temperature 15-30&deg;C (59-86&deg;F).</p><p>Store in the original package in order to protect from light and moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in polyamide/PVC/aluminum blister package in:</p><p>&nbsp;</p><p>Blisters in packages of: 7, 10, 14, 20, 28, 30, 50, 56, 98, 100, 140 and 200&nbsp;tablets.</p><p>Blisters (unit doses), in packages of: 49, 50 and 56&nbsp;tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
Organon Pharma (UK) Limited, Shotton Lane,
Cramlington, Northumberland, NE23 3JU,
UK.

Marketing Authorization Holder:
SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MAY 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>